Northfield Laboratories: Difference between revisions
→External links: the company offical website is no longer active |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5 |
||
(20 intermediate revisions by 16 users not shown) | |||
Line 1: | Line 1: | ||
{{More citations needed|date=November 2019}} |
|||
⚫ | '''Northfield Laboratories Inc.''' ( |
||
{{Infobox company |
|||
It was founded in 1985 and has since been a mainly [[Research and Development]] company. Northfield's only product was [[PolyHeme]], an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration|FDA]] regulatory approval. On May 9, 2009, after being informed by the [[Food and Drug Administration|FDA]] the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story, retrieved May 9, 2009</ref> |
|||
| name = Northfield Laboratories Inc. |
|||
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html</ref> |
|||
| logo = |
|||
| logo_size = |
|||
| logo_alt = |
|||
| logo_caption = |
|||
| logo_padding = |
|||
| image = |
|||
| image_size = |
|||
| image_alt = |
|||
| image_caption = |
|||
| trading_name = |
|||
| native_name = |
|||
| native_name_lang = <!-- Use ISO 639-1 code, e.g. "fr" for French. For multiple names in different languages, use {{Lang|[code]|[name]}}. --> |
|||
| romanized_name = |
|||
| former_name = |
|||
| type = |
|||
| traded_as = |
|||
| ISIN = |
|||
| industry = |
|||
| genre = |
|||
| fate = |
|||
| predecessor = <!-- or: |
|||
| predecessors = --> |
|||
| successor = <!-- or: |
|||
| successors = --> |
|||
| founded = 1985 |
|||
| founder = <!-- or: |
|||
| founders = --> |
|||
| defunct = {{End date|2009|05|09}} |
|||
| hq_location = |
|||
| hq_location_city = [[Evanston, Illinois]] |
|||
| hq_location_country = |
|||
| num_locations = |
|||
| num_locations_year = <!-- Year of num_locations data (if known) --> |
|||
| area_served = <!-- or: |
|||
| areas_served = --> |
|||
| key_people = |
|||
| products = [[PolyHeme]] |
|||
| brands = |
|||
| production = |
|||
| production_year = <!-- Year of production data (if known) --> |
|||
| services = |
|||
| revenue = |
|||
| revenue_year = <!-- Year of revenue data (if known) --> |
|||
| operating_income = |
|||
| income_year = <!-- Year of operating_income data (if known) --> |
|||
| net_income = <!-- or: |
|||
| profit = --> |
|||
| net_income_year = <!-- or: |
|||
| profit_year = --><!-- Year of net_income/profit data (if known) --> |
|||
| aum = <!-- Only for financial-service companies --> |
|||
| assets = |
|||
| assets_year = <!-- Year of assets data (if known) --> |
|||
| equity = |
|||
| equity_year = <!-- Year of equity data (if known) --> |
|||
| owner = <!-- or: |
|||
| owners = --> |
|||
| members = |
|||
| members_year = <!-- Year of members data (if known) --> |
|||
| num_employees = |
|||
| num_employees_year = <!-- Year of num_employees data (if known) --> |
|||
| parent = |
|||
| divisions = |
|||
| subsid = |
|||
| module = <!-- Used to embed other templates --> |
|||
| ratio = <!-- Basel III ratio, for BANKS ONLY --> |
|||
| rating = <!-- credit rating, for BANKS ONLY --> |
|||
| website = <!-- {{URL|example.com}} --> |
|||
| footnotes = |
|||
| intl = <!-- Set positively ("true"/"yes"/etc) if company is international, otherwise omit --> |
|||
}} |
|||
⚫ | '''Northfield Laboratories Inc.''' (former NASDAQ: '''NFLD''') was the maker of [[PolyHeme]], a [[Hemoglobin-based oxygen carriers|hemoglobin-based oxygen carrier]] (HBOC). The company was based in [[Evanston, Illinois]], with Dr. Steven A. Gould as its [[chief executive officer]]. As of May 31, 2005, the company had 68 employees. |
||
It was founded in 1985 and has since been a mainly [[research and development]] company. Northfield's only product was PolyHeme, an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration]] (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>{{cite web |url=http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story |title=Northfield Labs shuts operations |website=www.chicagotribune.com |access-date=May 9, 2009 |archive-date=May 12, 2009 |archive-url=https://web.archive.org/web/20090512103530/http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story |url-status=live }}</ref> The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>{{cite web |last1=Rhee |first1=Joseph |title=Test of Controversial Artificial Blood Product a Failure |url=http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html |website=ABCNews |archive-url=https://web.archive.org/web/20071218222258/http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html |archive-date=December 18, 2007 |date=May 23, 2007 |url-status=dead}}</ref> |
|||
==See also== |
==See also== |
||
* [[Clinical trial]] |
* [[Clinical trial]] |
||
* [[Urgent care]] |
* [[Urgent care]] |
||
* [[Unethical Human Experimentation in the United States]] |
|||
==References== |
==References== |
||
{{Reflist}} |
|||
<references/> |
|||
==External links== |
==External links== |
||
* [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6914127&OS=6914127&RS=6914127 PolyHeme's patent.] |
* [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6914127&OS=6914127&RS=6914127 PolyHeme's patent.] |
||
{{Authority control}} |
|||
[[Category:Chemical companies of the United States]] |
[[Category:Chemical companies of the United States]] |
||
[[Category:Transfusion medicine]] |
[[Category:Transfusion medicine]] |
||
[[Category:Companies formerly listed on |
[[Category:Companies formerly listed on the Nasdaq]] |
||
[[Category:Companies based in Evanston, Illinois]] |
[[Category:Companies based in Evanston, Illinois]] |
||
Latest revision as of 21:50, 11 July 2024
This article needs additional citations for verification. (November 2019) |
Founded | 1985 |
---|---|
Defunct | May 9, 2009 |
Headquarters | |
Products | PolyHeme |
Northfield Laboratories Inc. (former NASDAQ: NFLD) was the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC). The company was based in Evanston, Illinois, with Dr. Steven A. Gould as its chief executive officer. As of May 31, 2005, the company had 68 employees.
It was founded in 1985 and has since been a mainly research and development company. Northfield's only product was PolyHeme, an oxygen-carrying blood substitute, which failed to receive Food and Drug Administration (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.[1] The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.[2]
See also
[edit]References
[edit]- ^ "Northfield Labs shuts operations". www.chicagotribune.com. Archived from the original on May 12, 2009. Retrieved May 9, 2009.
- ^ Rhee, Joseph (May 23, 2007). "Test of Controversial Artificial Blood Product a Failure". ABCNews. Archived from the original on December 18, 2007.
External links
[edit]